Literature DB >> 18405972

Blood counts at time of complete remission provide additional independent prognostic information in acute myeloid leukemia.

Masamitsu Yanada1, Gautam Borthakur, Guillermo Garcia-Manero, Farhad Ravandi, Stefan Faderl, Sherry Pierce, Hagop Kantarjian, Elihu Estey.   

Abstract

Prognostic relevance of blood counts at complete remission (CR) in acute myeloid leukemia (AML) is not clear. To address this issue, we analyzed 891 AML patients in first CR. From the data of randomly selected 446 patients (training set), we first established optimal cutoffs for neutrophil and platelet counts and hemoglobin level at CR in terms of relapse-free survival (RFS). Patients whose counts were higher than each optimal cutoff were shown to have significantly better RFS (p<0.01 for neutrophil and platelets, and p=0.02 for hemoglobin). Then we tested whether these cutoffs were, after accounting for better known prognostic covariates, also predictive of RFS in the remaining 445 patients (validation set). Our data revealed that higher neutrophil count was independently predictive of longer RFS in the validation set (hazard ratio 1.38, p=0.02), as was higher platelet count (hazard ratio 1.35, p=0.04). These findings suggest that blood counts at CR, information readily available, are useful in prognostication in AML.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18405972      PMCID: PMC4182927          DOI: 10.1016/j.leukres.2008.03.002

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  17 in total

1.  FLT3 mutation and response to intensive chemotherapy in young adult and elderly patients with normal karyotype.

Authors:  Miloslav Beran; Rajyalakshmi Luthra; Hagop Kantarjian; Elihu Estey
Journal:  Leuk Res       Date:  2004-06       Impact factor: 3.156

2.  The quality of molecular response to chemotherapy is predictive for the outcome of AML1-ETO-positive AML and is independent of pretreatment risk factors.

Authors:  M Weisser; C Haferlach; W Hiddemann; S Schnittger
Journal:  Leukemia       Date:  2007-03-22       Impact factor: 11.528

3.  A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties.

Authors:  K Wheatley; A K Burnett; A H Goldstone; R G Gray; I M Hann; C J Harrison; J K Rees; R F Stevens; H Walker
Journal:  Br J Haematol       Date:  1999-10       Impact factor: 6.998

4.  Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification.

Authors:  J F San Miguel; M B Vidriales; C López-Berges; J Díaz-Mediavilla; N Gutiérrez; C Cañizo; F Ramos; M J Calmuntia; J J Pérez; M González; A Orfao
Journal:  Blood       Date:  2001-09-15       Impact factor: 22.113

Review 5.  Acute myeloid leukaemia.

Authors:  Elihu Estey; Hartmut Döhner
Journal:  Lancet       Date:  2006-11-25       Impact factor: 79.321

6.  Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from cancer and leukemia group B study 8461.

Authors:  Guido Marcucci; Krzysztof Mrózek; Amy S Ruppert; Kellie J Archer; Mark J Pettenati; Nyla A Heerema; Andrew J Carroll; Prasad R K Koduru; Jonathan E Kolitz; Lisa J Sterling; Colin G Edwards; John Anastasi; Richard A Larson; Clara D Bloomfield
Journal:  J Clin Oncol       Date:  2004-06-15       Impact factor: 44.544

7.  Independent prognostic significance of day 21 cytogenetic findings in newly-diagnosed acute myeloid leukemia or refractory anemia with excess blasts.

Authors:  Marina Konopleva; Su-Chun Cheng; Jorge E Cortes; Kimberly J Hayes; Sherry A Pierce; Michael Andreeff; Francis J Giles; Susan O'Brien; Hagop M Kantarjian; Elihu H Estey
Journal:  Haematologica       Date:  2003-07       Impact factor: 9.941

8.  Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations.

Authors:  P Gorello; G Cazzaniga; F Alberti; M G Dell'Oro; E Gottardi; G Specchia; G Roti; R Rosati; M F Martelli; D Diverio; F Lo Coco; A Biondi; G Saglio; C Mecucci; B Falini
Journal:  Leukemia       Date:  2006-06       Impact factor: 11.528

9.  Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia.

Authors:  Wolfgang Kern; Daniela Voskova; Claudia Schoch; Wolfgang Hiddemann; Susanne Schnittger; Torsten Haferlach
Journal:  Blood       Date:  2004-07-29       Impact factor: 22.113

10.  Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA).

Authors:  Claude Preudhomme; Christophe Sagot; Nicolas Boissel; Jean-Michel Cayuela; Isabelle Tigaud; Stéphane de Botton; Xavier Thomas; Emmanuel Raffoux; Charlotte Lamandin; Sylvie Castaigne; Pierre Fenaux; Hervé Dombret
Journal:  Blood       Date:  2002-10-15       Impact factor: 22.113

View more
  9 in total

Review 1.  Bone marrow evaluation for diagnosis and monitoring of acute myeloid leukemia.

Authors:  Mary-Elizabeth Percival; Catherine Lai; Elihu Estey; Christopher S Hourigan
Journal:  Blood Rev       Date:  2017-02-02       Impact factor: 8.250

2.  Low platelet count reduces subsequent complete remission rate despite marrow with <5% blasts after AML induction therapy.

Authors:  X Chen; L F Newell; H Xie; R B Walter; J M Pagel; V K Sandhu; P S Becker; P C Hendrie; J L Abkowitz; F R Appelbaum; E H Estey
Journal:  Leukemia       Date:  2015-02-04       Impact factor: 11.528

Review 3.  Acute myeloid leukemia with normal cytogenetics.

Authors:  Raya Mawad; Elihu H Estey
Journal:  Curr Oncol Rep       Date:  2012-10       Impact factor: 5.075

4.  Absolute lymphocyte counts refine minimal residual disease-based risk stratification in childhood acute lymphoblastic leukemia.

Authors:  Karen R Rabin; M Monica Gramatges; Michael J Borowitz; Shana L Palla; Xiaodong Shi; Judith F Margolin; Patrick A Zweidler-McKay
Journal:  Pediatr Blood Cancer       Date:  2011-11-18       Impact factor: 3.167

5.  Dynamic trajectory of platelet counts after the first cycle of induction chemotherapy in AML patients.

Authors:  Yazhen Bi; Zhaohui Wang; Saran Feng; Yan Wang; Yang Zhao; Hong Li; Jingyi Yu; Qian Liu; Chuansheng Zhu; Mingzhuo Li
Journal:  BMC Cancer       Date:  2022-05-01       Impact factor: 4.638

6.  The Impact of Early Versus Late Platelet and Neutrophil Recovery after Induction Chemotherapy on Survival Outcomes of Patients with Acute Myeloid Leukemia

Authors:  Rafiye Çiftçiler; İbrahim C. Haznedaroğlu; Nilgün Sayınalp; Osman Özcebe; Salih Aksu; Haluk Demiroğlu; Hakan Göker; Ümit Yavuz Malkan; Yahya Büyükaşık
Journal:  Turk J Haematol       Date:  2019-09-02       Impact factor: 1.831

7.  Combined use of peripheral blood blast count and platelet count during and after induction therapy to predict prognosis in children with acute lymphoblastic leukemia.

Authors:  Qingkai Dai; Rui Shi; Ge Zhang; Hui Yang; Yuefang Wang; Lei Ye; Luyun Peng; Siqi Guo; Jiajing He; Yongmei Jiang
Journal:  Medicine (Baltimore)       Date:  2021-04-16       Impact factor: 1.817

8.  Early platelet elevation after complete remission as a prognostic marker of favourable outcomes in favourable- and intermediate-risk acute myeloid leukaemia: A retrospective study.

Authors:  Xiaoling Wen; Ruoqi Li; Xialin Zhang; Jiahong Zhai; Suxia Yang; Yaozi Wang; Yanhong Tan; Zhifang Xu; Linhua Yang; Ruijuan Zhang
Journal:  J Clin Lab Anal       Date:  2022-01-03       Impact factor: 2.352

9.  Prognostic value of platelet recovery degree before and after achieving minimal residual disease negative complete remission in acute myeloid leukemia patients.

Authors:  Yang Wang; Hua Wang; Weida Wang; Wenjian Liu; Nawei Liu; Shuang Liu; Yue Lu
Journal:  BMC Cancer       Date:  2020-08-05       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.